Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy

Leuk Lymphoma. 2014 Apr;55(4):934-7. doi: 10.3109/10428194.2013.812788. Epub 2013 Jul 25.

Authors

Mette Ilander¹, Perttu Koskenvesa, Sari Hernesniemi, Thomas Lion, Kimmo Porkka, Satu Mustjoki

Affiliation

¹ Hematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital , Helsinki , Finland.

PMID: 23777365
DOI: 10.3109/10428194.2013.812788

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antineoplastic Agents / therapeutic use
Female
Fusion Proteins, bcr-abl / genetics*
Humans
Interferon-alpha / administration & dosage
Interferon-alpha / adverse effects
Interferon-alpha / therapeutic use*
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Leukemia, Myeloid, Chronic-Phase / genetics*
Mutation*
Protein Kinase Inhibitors / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents
Interferon-alpha
Protein Kinase Inhibitors
Fusion Proteins, bcr-abl